Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness byincreasing flexibility and distribution efficiency of ...

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025 ...

Emergent BioSolutions received Food and Drug Administration approval for its multipack configuration of Narcan, the opioid-overdose-reversal drug.

Emergent was “an obscure contractor in an obscure corner of the federal bureaucracy,” according to reporters at the New York Times who began looking into its operations as Covid unfolded, “applying ...

Emergent BioSolutions, Inc. (NYSE:EBS) shares surged higher Thursday after the company announced operational changes to stabilize its financial position and reported first-quarter financial results.

Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2, ...

An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into ...

GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced the introduction of a new NARCANDirect™ distribution center in Nevada to further demonstrate its ...

Emergent BioSolutions (NYSE:EBS) stock is trading higher on Thursday after the company announced the sale of its facility in Baltimore-Camden to Bora Pharmaceuticals. What Happened: On Thursday prior ...

Johnson & Johnson and Emergent BioSolutions pointed blame at each other June 6 for breaking agreements in a COVID-19 vaccine supply contract, according to the Wall Street Journal. Emergent ...